Medlab has approval to supply NanaBis™ under the TGA's Special Access Scheme.
() is on schedule with recruitment for the clinical trial of its cannabis-based cancer medicine, NanaBis™, at Royal North Shore Hospital in Sydney.
The trial will test the safety, efficacy and dose tolerance in cancer patients with both managed and unmanaged pain.
READ: Medlab Clinical begins trial of cannabis-based cancer pain management medicine
The recruitment update coincides with separate positive feedback received from doctors who have been prescribing the medicine.
Feedback from some doctors is that it is proving effective in decreasing reliance on opioids and in its speed of action, aided by delivery through Medlab’s nano-particle spray, NanoCelle™
Under the Therapeutic Goods Administration’s (TGA) Special Access Scheme, Medlab has approval to supply NanaBis™ to medical practitioners for use with patients suffering cancer pain.
NanaBis™ is one of two developed formulas
Medlab has developed two cannabis-based medicines which have differing cannabis formulations, NanaBis™ and NanaBidial™.
NanaBis™ for those with chronic caner pain which is a whole cannabis plant extract of 1:1 ratios, CBD to THC
NanaBidial™ is for those suffering effects from chemotherapy is similar in all ways to NanaBis™ except the ratio is 18 parts CBD to 1 part THC.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE